SEC Info - Bronfman Edgar Jr. - ‘4’ for 7/7/20 re: Accolade, Inc.

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

BRONFMAN EDGAR JR

(Last)

(First)

(Middle)

C/O ACCRETIVE, LLC, 660 MADISON

AVENUE, 12TH FLOOR, SUITE 1215

(Street)

NEW YORK

10065

(City)

(State)

(Zip)

2. Issuer Name and Ticker or Trading Symbol
Accolade, Inc. [ ACCD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

Director	X	10% Owner
Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
7/7/20

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	7/7/20		C		51,420	A	⁽¹⁾	51,420	I	By Accretive Care Holding Partnership ⁽²⁾
Common Stock	7/7/20		C		38,314	A	⁽³⁾	89,734	I	By Accretive Care Holding Partnership ⁽²⁾
Common Stock	7/7/20		C		31,357	A	⁽⁴⁾	121,091	I	By Accretive Care Holding Partnership ⁽²⁾
Common Stock	7/7/20		C		7,869	A	⁽⁵⁾	128,960	I	By Accretive Care Holding Partnership ⁽²⁾
Common Stock	7/7/20		C		1	A	⁽⁶⁾	128,961	I	By Accretive Care Holding Partnership ⁽²⁾
Common Stock	7/7/20		C		426,473	A	⁽¹⁾	426,473	I	By Accretive Coinvestment Partners, LLC ⁽⁷⁾
Common Stock	7/7/20		C		360,936	A	⁽³⁾	787,409	I	By Accretive Coinvestment Partners, LLC ⁽⁷⁾
Common Stock	7/7/20		C		273,901	A	⁽⁴⁾	1,061,310	I	By Accretive Coinvestment Partners, LLC ⁽⁷⁾
Common Stock	7/7/20		C		68,910	A	⁽⁵⁾	1,130,220	I	By Accretive Coinvestment Partners, LLC ⁽⁷⁾
Common Stock	7/7/20		C		1	A	⁽⁸⁾	1,130,221	I	By Accretive Coinvestment Partners, LLC ⁽⁷⁾
Common Stock	7/7/20		C		429,344	A	⁽¹⁾	429,344	I	By Accretive II Coinvestment, L.P. ⁽⁹⁾
Common Stock	7/7/20		C		319,920	A	⁽³⁾	749,264	I	By Accretive II Coinvestment, L.P. ⁽⁹⁾
Common Stock	7/7/20		C		261,818	A	⁽⁴⁾	1,011,082	I	By Accretive II Coinvestment, L.P. ⁽⁹⁾
Common Stock	7/7/20		C		65,713	A	⁽⁵⁾	1,076,795	I	By Accretive II Coinvestment, L.P. ⁽⁹⁾
Common Stock	7/7/20		C		1	A	⁽¹⁰⁾	1,076,796	I	By Accretive II Coinvestment, L.P. ⁽⁹⁾
Common Stock	7/7/20		C		1,313,268	A	⁽¹⁾	1,313,268	I	By Accretive II, L.P. ⁽¹¹⁾
Common Stock	7/7/20		C		978,566	A	⁽³⁾	2,291,834	I	By Accretive II, L.P. ⁽¹¹⁾
Common Stock	7/7/20		C		800,845	A	⁽⁴⁾	3,092,679	I	By Accretive II, L.P. ⁽¹¹⁾
Common Stock	7/7/20		C		201,002	A	⁽⁵⁾	3,293,681	I	By Accretive II, L.P. ⁽¹¹⁾
Common Stock	7/7/20		C		2	A	⁽¹²⁾	3,293,683	I	By Accretive II, L.P. ⁽¹¹⁾
Common Stock	7/7/20		C		1,794,034	A	⁽¹⁾	1,794,034	I	By Accretive Investors SBIC, LP ⁽¹³⁾
Common Stock	7/7/20		C		1,336,804	A	⁽³⁾	3,130,838	I	By Accretive Investors SBIC, LP ⁽¹³⁾
Common Stock	7/7/20		C		1,094,020	A	⁽⁴⁾	4,224,858	I	By Accretive Investors SBIC, LP ⁽¹³⁾
Common Stock	7/7/20		C		274,586	A	⁽⁵⁾	4,499,444	I	By Accretive Investors SBIC, LP ⁽¹³⁾
Common Stock	7/7/20		C		3	A	⁽¹⁴⁾	4,499,447	I	By Accretive Investors SBIC, LP ⁽¹³⁾

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Series A-1 Preferred Stock	⁽¹⁾	7/7/20		C		45,598		⁽¹⁾	⁽¹⁾	Common Stock	51,420	$0.00	0	I	By Accretive Care Holding Partnership ⁽²⁾
Series A-2 Preferred Stock	⁽³⁾	7/7/20		C		32,575		⁽³⁾	⁽³⁾	Common Stock	38,314	$0.00	0	I	By Accretive Care Holding Partnership ⁽²⁾
Series B Preferred Stock	⁽⁴⁾	7/7/20		C		26,356		⁽⁴⁾	⁽⁴⁾	Common Stock	31,357	$0.00	0	I	By Accretive Care Holding Partnership ⁽²⁾
Series C Preferred Stock	⁽⁵⁾	7/7/20		C		5,146		⁽⁵⁾	⁽⁵⁾	Common Stock	7,869	$0.00	0	I	By Accretive Care Holding Partnership ⁽²⁾
Series A-1 Preferred Stock	⁽¹⁾	7/7/20		C		378,186		⁽¹⁾	⁽¹⁾	Common Stock	426,473	$0.00	0	I	By Accretive Coinvestment Partners, LLC ⁽⁷⁾
Series A-2 Preferred Stock	⁽³⁾	7/7/20		C		306,871		⁽³⁾	⁽³⁾	Common Stock	360,936	$0.00	0	I	By Accretive Coinvestment Partners, LLC ⁽⁷⁾
Series B Preferred Stock	⁽⁴⁾	7/7/20		C		230,215		⁽⁴⁾	⁽⁴⁾	Common Stock	273,901	$0.00	0	I	By Accretive Coinvestment Partners, LLC ⁽⁷⁾
Series C Preferred Stock	⁽⁵⁾	7/7/20		C		45,061		⁽⁵⁾	⁽⁵⁾	Common Stock	68,910	$0.00	0	I	By Accretive Coinvestment Partners, LLC ⁽⁷⁾
Series A-1 Preferred Stock	⁽¹⁾	7/7/20		C		380,732		⁽¹⁾	⁽¹⁾	Common Stock	429,344	$0.00	0	I	By Accretive II Coinvestment, L.P. ⁽⁹⁾
Series A-2 Preferred Stock	⁽³⁾	7/7/20		C		271,999		⁽³⁾	⁽³⁾	Common Stock	319,920	$0.00	0	I	By Accretive II Coinvestment, L.P. ⁽⁹⁾
Series B Preferred Stock	⁽⁴⁾	7/7/20		C		220,059		⁽⁴⁾	⁽⁴⁾	Common Stock	261,818	$0.00	0	I	By Accretive II Coinvestment, L.P. ⁽⁹⁾
Series C Preferred Stock	⁽⁵⁾	7/7/20		C		42,970		⁽⁵⁾	⁽⁵⁾	Common Stock	65,713	$0.00	0	I	By Accretive II Coinvestment, L.P. ⁽⁹⁾
Series A-1 Preferred Stock	⁽¹⁾	7/7/20		C		1,164,574		⁽¹⁾	⁽¹⁾	Common Stock	1,313,268	$0.00	0	I	By Accretive II, L.P. ⁽¹¹⁾
Series A-2 Preferred Stock	⁽³⁾	7/7/20		C		831,986		⁽³⁾	⁽³⁾	Common Stock	978,566	$0.00	0	I	By Accretive II, L.P. ⁽¹¹⁾
Series B Preferred Stock	⁽⁴⁾	7/7/20		C		673,113		⁽⁴⁾	⁽⁴⁾	Common Stock	800,845	$0.00	0	I	By Accretive II, L.P. ⁽¹¹⁾
Series C Preferred Stock	⁽⁵⁾	7/7/20		C		131,436		⁽⁵⁾	⁽⁵⁾	Common Stock	201,002	$0.00	0	I	By Accretive II, L.P. ⁽¹¹⁾
Series A-1 Preferred Stock	⁽¹⁾	7/7/20		C		1,590,905		⁽¹⁾	⁽¹⁾	Common Stock	1,794,034	$0.00	0	I	By Accretive Investors SBIC, LP ⁽¹³⁾
Series A-2 Preferred Stock	⁽³⁾	7/7/20		C		1,136,563		⁽³⁾	⁽³⁾	Common Stock	1,336,804	$0.00	0	I	By Accretive Investors SBIC, LP ⁽¹³⁾
Series B Preferred Stock	⁽⁴⁾	7/7/20		C		919,528		⁽⁴⁾	⁽⁴⁾	Common Stock	1,094,020	$0.00	0	I	By Accretive Investors SBIC, LP ⁽¹³⁾
Series C Preferred Stock	⁽⁵⁾	7/7/20		C		179,553		⁽⁵⁾	⁽⁵⁾	Common Stock	274,586	$0.00	0	I	By Accretive Investors SBIC, LP ⁽¹³⁾

Explanation of Responses:

(1) The Series A-1 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1.127681818 basis immediately upon closing of the Issuer's initial public offering and had no expiration date.

(2) The shares reported herein are held of record by Accretive Care Holding Partnership. Accretive II GP, LLC is the general partner of Accretive Care Holding Partnership. The Reporting Person and J. Michael Cline are the managing members of Accretive II GP, LLC, and may be deemed to have shared voting and dispositive power with respect to the shares held by Accretive Care Holding Partnership. The Reporting Person disclaims beneficial ownership of such securities.

(3) The Series A-2 Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1.176181818 basis immediately upon closing of the Issuer's initial public offering and had no expiration date.

(4) The Series B Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1.18976363636364 basis immediately upon closing of the Issuer's initial public offering and had no expiration date.

(5) The Series C Preferred Stock automatically converted into shares of Common Stock of the Issuer on a 1:1.52927954545455 basis immediately upon closing of the Issuer's initial public offering and had no expiration date.

(6) Under the terms of the Issuer's Seventh Amended and Restated Certificate of Incorporation, no fractional shares were issued upon the conversion of any share or shares of its Preferred Stock after aggregating all shares owned thereof. This 1 share represents the aggregate total of all fractional shares that Accretive Care Holding Partnership was entitled to receive following the conversion of the Preferred Stock that it held.

(7) The shares reported herein are held of record by Accretive Coinvestment Partners, LLC. Accretive Associates I, LLC is the managing member of Accretive Coinvestment Partners, LLC. The Reporting Person and J. Michael Cline are the managing members of Accretive Associates I, LLC, and may be deemed to have shared voting and dispositive power with respect to the shares held by Accretive Coinvestment Partners, LLC. The Reporting Person disclaims beneficial ownership of such securities.

(8) Under the terms of the Issuer's Seventh Amended and Restated Certificate of Incorporation, no fractional shares were to be issued upon the conversion of any share or shares of its Preferred Stock after aggregating all shares owned thereof. This 1 share represents that aggregate total of all fractional shares that Accretive Coinvestment Partners, LLC was entitled to receive following the conversion of the Preferred Stock that it held.

(9) The shares reported herein are held of record by Accretive II Coinvestment, L.P. Accretive II GP, LLC is the general partner of Accretive II Coinvestment, L.P. The Reporting Person and J. Michael Cline are the managing members of Accretive II GP, LLC, and may be deemed to have shared voting and dispositive power with respect to the shares held by Accretive II Coinvestment, L.P. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

(10) Under the terms of the Issuer's Seventh Amended and Restated Certificate of Incorporation, no fractional shares were issued upon the conversion of any share or shares of its Preferred Stock after aggregating all shares owned thereof. This 1 share represents the aggregate total of all fractional shares that Accretive II Coinvestment, L.P. was entitled to receive following the conversion of the Preferred Stock that it held.

(11) The shares reported herein are held of record by Accretive II, L.P. Accretive II GP, LLC is the general partner of Accretive II, L.P. The Reporting Person and J. Michael Cline are the managing members of Accretive II GP, LLC, and may be deemed to have shared voting and dispositive power with respect to the shares held by Accretive II, L.P. The Reporting Person disclaims beneficial ownership of such securities.

(12) Under the terms of the Issuer's Seventh Amended and Restated Certificate of Incorporation, no fractional shares were issued upon the conversion of any share or shares of its Preferred Stock after aggregating all shares owned thereof. These 2 shares represent the aggregate total of all fractional shares that Accretive II, L.P. was entitled to receive following the conversion of the Preferred Stock that it held.

(13) The shares reported herein are held of record by Accretive Investors SBIC, L.P. Accretive Associates SBIC, LLC is the general partner of Accretive Investors SBIC, L.P. The Reporting Person and J. Michael Cline are the managing members of Accretive Associates SBIC, LLC, and may be deemed to have shared voting and dispositive power with respect to the shares held by Accretive Investors SBIC, L.P. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.

(14) Under the terms of the Issuer's Seventh Amended and Restated Certificate of Incorporation, no fractional shares were issued upon the conversion of any share or shares of its Preferred Stock after aggregating all shares owned thereof. These 3 shares represent the aggregate total of all fractional shares that Accretive Investors SBIC, LP was entitled to receive following the conversion of the Preferred Stock that it held.

Remarks:

Additional reporting persons are: Accretive II, L.P., Accretive II Coinvestment, L.P., Accretive Care Holding Partnership, Accretive II GP, LLC, Accretive Investors SBIC, L.P., Accretive Associates SBIC, LLC, Accretive Coinvestment Partners, LLC and Accretive Associates I, LLC.

	/s/ Edgar Bronfman, Jr.	7/8/20
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

____________ Transaction Code:
C	Conversion of derivative security.

Bronfman Edgar Jr. – ‘4’ for 7/7/20 re: Accolade, Inc.

On: Friday, 7/10/20, at 6:43am ET · As of: 7/8/20 · For: 7/7/20 · Accession #: 899243-20-18778 · File #: 1-39348

Previous ‘4’: ‘4’ on 6/30/20 for 6/28/20 · Next: ‘4’ on 10/14/20 for 10/13/20 · Latest: ‘4’ on 7/8/21 for 7/6/21

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34
Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Bronfman Edgar Jr. – ‘4’ for 7/7/20 re: Accolade, Inc.

On: Friday, 7/10/20, at 6:43am ET · As of: 7/8/20 · For: 7/7/20 · Accession #: 899243-20-18778 · File #: 1-39348

Previous ‘4’: ‘4’ on 6/30/20 for 6/28/20 · Next: ‘4’ on 10/14/20 for 10/13/20 · Latest: ‘4’ on 7/8/21 for 7/6/21

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34Filing Table of Contents

This ‘4’ Document is an XML Data File that may be rendered in various formats:

Statement of Changes in Beneficial Ownership of Securities by an Insider — Form 4 — SEA’34
Filing Table of Contents